258 related articles for article (PubMed ID: 32721477)
21. MicroRNA in prostate cancer: Practical aspects.
Patil PA; Magi-Galluzzi C
Histol Histopathol; 2015 Dec; 30(12):1379-96. PubMed ID: 26186079
[TBL] [Abstract][Full Text] [Related]
22. Identification of Potential miRNAs Biomarkers for High-Grade Prostate Cancer by Integrated Bioinformatics Analysis.
Foj L; Filella X
Pathol Oncol Res; 2019 Oct; 25(4):1445-1456. PubMed ID: 30367364
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic, prognostic and predictive value of cell-free miRNAs in prostate cancer: a systematic review.
Endzeliņš E; Melne V; Kalniņa Z; Lietuvietis V; Riekstiņa U; Llorente A; Linē A
Mol Cancer; 2016 May; 15(1):41. PubMed ID: 27189160
[TBL] [Abstract][Full Text] [Related]
24. MicroRNAs associated with metastatic prostate cancer.
Watahiki A; Wang Y; Morris J; Dennis K; O'Dwyer HM; Gleave M; Gout PW; Wang Y
PLoS One; 2011; 6(9):e24950. PubMed ID: 21980368
[TBL] [Abstract][Full Text] [Related]
25. miR-34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression.
Corcoran C; Rani S; O'Driscoll L
Prostate; 2014 Sep; 74(13):1320-34. PubMed ID: 25053345
[TBL] [Abstract][Full Text] [Related]
26. MicroRNAs in prostate cancer: Functional role as biomarkers.
Kanwal R; Plaga AR; Liu X; Shukla GC; Gupta S
Cancer Lett; 2017 Oct; 407():9-20. PubMed ID: 28823964
[TBL] [Abstract][Full Text] [Related]
27. A study of circulating microRNAs identifies a new potential biomarker panel to distinguish aggressive prostate cancer.
Farran B; Dyson G; Craig D; Dombkowski A; Beebe-Dimmer JL; Powell IJ; Podgorski I; Heilbrun L; Bolton S; Bock CH
Carcinogenesis; 2018 Apr; 39(4):556-561. PubMed ID: 29471417
[TBL] [Abstract][Full Text] [Related]
28. The Prostate Cancer Cells Resistant to Docetaxel as in vitro Model for Discovering MicroRNAs Predictive of the Onset of Docetaxel Resistance.
Bascetta L; Oliviero A; D'Aurizio R; Evangelista M; Mercatanti A; Pellegrini M; Marrocolo F; Bracarda S; Rizzo M
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28703747
[TBL] [Abstract][Full Text] [Related]
29. MicroRNAs as Biomarkers for Diagnosis, Prognosis and Theranostics in Prostate Cancer.
Bertoli G; Cava C; Castiglioni I
Int J Mol Sci; 2016 Mar; 17(3):421. PubMed ID: 27011184
[TBL] [Abstract][Full Text] [Related]
30. Micrornas in prostate cancer: an overview.
Vanacore D; Boccellino M; Rossetti S; Cavaliere C; D'Aniello C; Di Franco R; Romano FJ; Montanari M; La Mantia E; Piscitelli R; Nocerino F; Cappuccio F; Grimaldi G; Izzo A; Castaldo L; Pepe MF; Malzone MG; Iovane G; Ametrano G; Stiuso P; Quagliuolo L; Barberio D; Perdonà S; Muto P; Montella M; Maiolino P; Veneziani BM; Botti G; Caraglia M; Facchini G
Oncotarget; 2017 Jul; 8(30):50240-50251. PubMed ID: 28445135
[TBL] [Abstract][Full Text] [Related]
31. The role of miRNA in prostate cancer diagnosis, prognosis and treatment response: a narrative review.
Vazquez-Urrutia JR; Torres-Bustamante MI; Cerda-Cruz CR; Bravo-Cuellar A; Ortiz-Lazareno PC
Future Oncol; 2023 Jan; 19(1):77-93. PubMed ID: 36705257
[TBL] [Abstract][Full Text] [Related]
32. Emerging role of microRNAs in prostate cancer: implications for personalized medicine.
Gandellini P; Folini M; Zaffaroni N
Discov Med; 2010 Mar; 9(46):212-8. PubMed ID: 20350487
[TBL] [Abstract][Full Text] [Related]
33. miRNAs associated with prostate cancer risk and progression.
Luu HN; Lin HY; Sørensen KD; Ogunwobi OO; Kumar N; Chornokur G; Phelan C; Jones D; Kidd L; Batra J; Yamoah K; Berglund A; Rounbehler RJ; Yang M; Lee SH; Kang N; Kim SJ; Park JY; Di Pietro G
BMC Urol; 2017 Mar; 17(1):18. PubMed ID: 28320379
[TBL] [Abstract][Full Text] [Related]
34. MicroRNAs as Diagnostic, Prognostic, and Therapeutic Biomarkers in Prostate Cancer.
Aghdam AM; Amiri A; Salarinia R; Masoudifar A; Ghasemi F; Mirzaei H
Crit Rev Eukaryot Gene Expr; 2019; 29(2):127-139. PubMed ID: 31679268
[TBL] [Abstract][Full Text] [Related]
35. MicroRNAs and the Response of Prostate Cancer to Anti-Cancer Drugs.
Pennati M; Folini M; Gandellini P; Zaffaroni N
Curr Drug Targets; 2016; 17(3):257-65. PubMed ID: 25777275
[TBL] [Abstract][Full Text] [Related]
36. The other face of miR-17-92a cluster, exhibiting tumor suppressor effects in prostate cancer.
Ottman R; Levy J; Grizzle WE; Chakrabarti R
Oncotarget; 2016 Nov; 7(45):73739-73753. PubMed ID: 27650539
[TBL] [Abstract][Full Text] [Related]
37. Comparative analysis of epi-miRNA expression levels in local/locally advanced and metastatic prostate cancer patients.
Gurbuz V; Kiliccioglu I; Dikmen AU; Bilen CY; Sozen S; Konac E
Gene; 2020 Oct; 758():144963. PubMed ID: 32683077
[TBL] [Abstract][Full Text] [Related]
38. MicroRNAs as Guardians of the Prostate: Those Who Stand before Cancer. What Do We Really Know about the Role of microRNAs in Prostate Biology?
Andl T; Ganapathy K; Bossan A; Chakrabarti R
Int J Mol Sci; 2020 Jul; 21(13):. PubMed ID: 32645914
[TBL] [Abstract][Full Text] [Related]
39. Androgen receptor and miR-206 regulation in prostate cancer.
Chua FY; Adams BD
Transcription; 2017; 8(5):313-327. PubMed ID: 28598253
[TBL] [Abstract][Full Text] [Related]
40. [The Role of MiRNAs in the Development of Prostate Cancer].
Kunsbaeva GB; Gilyazova IR; Pavlov VN; Khusnutdinova EK
Genetika; 2015 Jul; 51(7):737-53. PubMed ID: 26410927
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
